Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses
Research and development	$ 13,531	$ 7,410
General and administrative	4,433	3,459
Total operating expenses	17,964	10,869
Loss from operations	(17,964)	(10,869)
Other income, net	1,409	574
Change in fair value of warrant liabilities and fair value of financial instruments issued in excess of proceeds	10,060	(13,336)
Net loss	(6,495)	(23,631)
Other comprehensive loss:
Unrealized loss on available-for-sale securities, net	(44)
Comprehensive loss	$ (6,539)	$ (23,631)
Basic earnings per share of common stock (As Restated)	$ (0.08)	$ (0.65)
Diluted earnings per share of common stock (As Restated)	$ (0.08)	$ (0.65)
Weighted-average common shares outstanding, basic	77,126,763	29,989,400
Weighted-average common shares outstanding, diluted	77,126,763	29,989,400
Series X and Series X1 Non-Voting Convertible Preferred Stock [Member]
Other comprehensive loss:
Basic earnings per share (As Restated)	$ (4.32)	$ (36.12)
Diluted earnings per share (As Restated)	$ (4.32)	$ (36.12)
Weighted-average shares outstanding, basic (As Restated)	114,508	114,508
Weighted-average shares outstanding, diluted (As Restated)	114,508	114,508